A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer

In conclusion, TEADi is a valuable research tool for studying YAP1/TAZ and the Hippo pathway in cancer and other pathologies, with improved advantages that include rapid and simple inhibition of TEAD transcription and specific blockage of nuclear events mediated by both YAP1 and TAZ without affecting structural or cytoplasmic functions of these proteins.The NCILaboratory of Cellular and Molecular Biologyis seeking statements of capability or interest from parties interested in licensing this novel inhibitor of the Hippo signaling pathway.IC: NCINIH Ref. No.: E-108-2019Advantages: Rapid and simple inhibition of specific effectors of a signaling pathway frequently disrupted in cancerInhibition of both YAP1 and TAZ factors that regulate the Hippo pathwayInhibition of YAP/TAZ interaction with a specific family of transcription factorsGreen fluorescent protein (GFP) label for easy trackingNuclear localization signal to target hyperactivated YAP/TAZApplications: TEADi DNA construct to study Hippo signaling pathway in different pathologies and cellular systems.TEADi DNA construct to selectively shut off Hippo signaling pathway for broader research purposesDelivery of TEADi DNA construct using lentivirus, adenovirus (AV), or adeno-associated virus (AAV) for broad research purposesDevelopment Status: Pre-clinical (in vivo)Updated On: Apr 2, 2020Date Published: Thursday, April 2, 2020Lead Inventor: Inventor IC: NCINCIInventor Lab URL: h...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research